← All Clearpoint Neuro, INC filings

Clearpoint Neuro, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CLPT
Clearpoint Neuro, INC
10-K: ClearPoint Neuro Expands Portfolio with IRRAS Acquisition, Secures $50M Debt
ClearPoint Neuro reports increased revenue and significant net losses in 2025, driven by the IRRAS acquisition and new debt financing, while advancing its neurosurgical and drug delivery platforms.
NASDAQ
CLPT
Clearpoint Neuro, INC
10-K: ClearPoint Neuro Reports Increased Revenue and Reduced Losses in 2024 Annual Filing
ClearPoint Neuro's 2024 10-K filing reveals revenue growth driven by neurosurgery and biologics, alongside reduced operating losses and strategic financial maneuvers.
NASDAQ
CLPT
Clearpoint Neuro, INC
10-K: ClearPoint Neuro Details Share Structure and Corporate Governance in 10-K Filing
ClearPoint Neuro's 10-K filing outlines the company's share structure, voting rights, and corporate governance policies, including anti-takeover provisions.